Stroke/control mice showed robust staining for GSDMD in both the hippocampus and cortex, which was significantly reduced in the PBM‐treated group at 7 days post stroke compared to the stroke/control group (hippocampus: 184.81 ± 16.95% versus 275.12 ± 19.25%, stroke/PBM and stroke/control group, respectively, p < 0.01 (p = 0.007); cortex: 129.04 ± 18.41% versus 328.40 ± 30.13%, stroke/PBM and stroke/control, respectively, p < 0.01 (p = 0.001)), as presented in Figure 6c,d. The gene discussed is GSDMD; the disease is stroke disorder.